HSDT (Helius Medical Technologies, Inc.) Bathi resik saben saham (EPS TTM)

Helius Medical is scaling its proprietary neuromodulators and software across the global market. The issuer's revenues are based on the sale of PoNS systems for multiple sclerosis rehabilitation. However, a high burn rate and challenges with insurance coverage create financial risks. The annual net income per share growth rate (ttm) illustrates the rolling profit trend, where the value 99.80 reflects the current dynamics.

Helius Medical revenues depend on the commercialization of PoNS neurotechnologies, where sales efficiency determines final profit. By analyzing the EPS YoY TTM growth trajectory, an investor assesses the rolling annual growth in earnings per share, which reveals the actual profitability trend and eliminates reporting manipulations, thereby determining the current market consensus regarding business sustainability.